Showing 5251-5260 of 5689 results for "".
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMDhttps://modernod.com/news/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd/2476795/Opthea announced positive phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD). <
- TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug Candidatehttps://modernod.com/news/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease/2476792/TopiVert Pharma announced topline results from THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1, a multicenter, randomized, double-masked, placebo-controlled phase 2b/3
- Alimera Announces Iluvien Regulatory Approval in Australia for the Treatment of DMEhttps://modernod.com/news/alimera-announces-iluvien-regulatory-approval-in-australia-for-the-treatment-of-dme/2479552/Alimera Sciences announced that the Australian Therapeutic Goods Administration (TGA), the division of the Australian Department of Health that oversees the availability of medical products, has approved Iluvien (190 micrograms intravitreal implant in applicator) for the treatment of diabetic mac
- Staar Surgical Announces Submission of Presbyopia Clinical Trial Datahttps://modernod.com/news/staar-surgical-announces-submission-of-presbyopia-clinical-trial-data/2479554/Staar Surgical announced the submission of its multisite European pivotal clinical trial data for the EVO+ Visian ICL with Aspheric (EDOF) Optic, a lens that is designed to provide correction or reduction of myopia or hyperopia and presbyopia. Results from the clinical trial were submitted to DEK
- Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edemahttps://modernod.com/news/perspective-protocol-v-sheds-light-on-managing-mild-diabetic-macular-edema/2479555/When it comes to the treatment of diabetic macular edema (DME), ophthalmologists have overwhelming evidence to guide their decision-making—but only up to a point. DME consists of three clinical subcategories: center-involved DME (CI-DME) with visual acuity (VA) impairment, CI-DME with good
- US Outlines Plans to Allow Importation of Certain Prescription Drugs From Canada, Other Countrieshttps://modernod.com/news/us-outlines-plans-to-allow-importation-of-certain-prescription-drugs-from-canada-other-countries/2479556/The US Department of Health and Human Services (HHS) on Wednesday outlined details of two potential pathways that will allow the importation of certain prescription medicines originally intended for foreign markets. The announcement comes the day after HHS Secretary Alex Azar confirmed that Presi
- Acuity Eyecare Group Enters Texas Market With Multiple Acquisitionshttps://modernod.com/news/acuity-eyecare-group-enters-texas-market-with-multiple-acquisitions/2476785/Riata Capital Group announced that its portfolio company Acuity Eyecare Group, an owner and operator of North American eyecare groups and optometry practices, has acquired 11 regional eyecare practices in Texas. These acquisitions are the first for Acuity Eyecare
- CMS Issues Proposed 2020 ASC Payment Rulehttps://modernod.com/news/cms-issues-proposed-2020-asc-payment-rule/2479563/On July 29, the Centers for Medicare and Medicaid Services (CMS) issued its proposed CY 2020 payment rate regulation for hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs). The proposed regulation will soon be published in the Federal Register. The Outpatient Ophthalmic
- Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpointshttps://modernod.com/news/alkahest-phase-2a-study-akst4290-202-in-refractory-wet-amd-meets-primary-and-secondary-endpoints/2476778/Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 w
- European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10https://modernod.com/news/european-medicines-agency-grants-prime-access-to-proqrs-sepofarsen-for-lebers-congenital-amaurosis-10/2476779/ProQR Therapeutics announced that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the Priority Medicines (PRIME) program by the European Med